2026 Interim report
Filed with HKEX · Stock code 3880 · · 61 pages · English
2 Corporate Information 4 Financial Highlights 5 Business Highlights 7 Management Discussion and Analysis 22 Corporate Governance and Other Information 29 Independent Review Report 30 Interim Condensed Consolidated Statement of Profit or Loss 31 Interim Condensed Consolidated Statement of Comprehensive Income 32 Interim Condensed Consolidated Statement of Financial Position 34 Interim Condensed Co
Earlier from Medtide
- CPC Scientific Announces U.S. FDA Pre-License Inspection (PLI) Successfully Completed at Its Hangzhou cGMP Manufacturing Facility for Hepcludex® API, Establishing a Proven Track Record Under the Stringent BLA Pathway
- Articles of association
Later from Medtide
- Notification Letter and Reply Form to Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications
- Resignation of executive director
- List of directors and their roles and functions
- Voluntary announcement update on the strategic expansion of large-scale peptide CDMO production capacity
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Follow Medtide into a list and get an email when it puts out news.
Follow Medtide